VX-765
(Epilepsy)

VX-765 is a novel Caspase-1 inhibitor being investigated for the treatment of epilepsy.

VX-765 has been shown to inhibit acute seizures in preclinical models of acute epilepsy and has shown activity in preclinical models of chronic epilepsy that do not respond to standard anti-epileptic drugs.

In March 2011, Vertex announced results from a Phase 2 study of VX-765 that enrolled 60 people with treatment-resistant partial onset epilepsy, which is a type of epilepsy where the seizures start and occur in a specific part of the brain. Based on these results, Vertex plans to begin a larger and longer-duration Phase 2b study of VX-765 in people with treatment-resistant epilepsy as early as the fourth quarter of 2011.